Welcome to our dedicated page for Olema Pharmaceuticals SEC filings (Ticker: OLMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Olema Pharmaceuticals, Inc. filings document the regulatory record of a clinical-stage oncology company with common stock listed on the Nasdaq Global Select Market under OLMA. The company’s disclosures cover its targeted-therapy pipeline, including palazestrant and OP-3136, as well as financial results, liquidity updates, capital-structure matters, and Regulation FD investor materials.
Olema’s SEC filings also record material agreements, including lease arrangements, and governance matters such as board appointments, officer departures, indemnification agreements, compensation arrangements, and equity awards. Proxy materials address director elections, executive compensation, equity incentive plans, pay-versus-performance disclosure, and shareholder voting matters.
Olema Pharmaceuticals, Inc. executive Austin Sasha Lu, the VP of Finance and Controller, filed an initial ownership report detailing equity holdings in the company. As of January 30, 2026, Lu directly holds 4,488 shares of common stock and multiple stock option awards. These stock options are structured to vest monthly over multi‑year periods, with several grants featuring 25% vesting on specified initial dates and the remaining 75% vesting in equal monthly installments, all contingent on continued service with Olema.
Janus Henderson Group plc filed an amended Schedule 13G reporting beneficial ownership of 6,710,194 shares of Olema Pharmaceuticals, Inc. common stock, representing 8.4% of the class as of 12/31/2025.
The stake is held through various Janus Henderson asset management subsidiaries in discretionary managed portfolios. These asset managers share voting and dispositive power over the shares, while the underlying managed portfolios receive all dividends and sale proceeds. No individual managed portfolio owns more than five percent of Olema’s common stock. Janus Henderson certifies the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Olema.
Bain Capital Life Sciences Opportunities IV, L.P. has reported a passive ownership stake in Olema Pharmaceuticals, Inc. common stock on a Schedule 13G/A. As of December 31, 2025, it is deemed to beneficially own 8,508,641 shares, representing 9.99% of the outstanding common stock.
The position consists of 1,989,775 common shares and pre-funded warrants initially exercisable for up to 8,013,216 additional shares, but a 9.99% “Beneficial Ownership Blocker” caps how many warrant shares are counted for regulatory purposes. The filing states the securities were not acquired to change or influence control of Olema.
Olema Pharmaceuticals, Inc. is the subject of an amended Schedule 13G filing in which Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report that they now beneficially own 0 shares of Olema common stock, representing 0.00% of the class.
The filing confirms they have no sole or shared voting or dispositive power over Olema shares and that they own 5% or less of the outstanding common stock. Ownership percentages are calculated using 78,652,730 Olema common shares outstanding as of November 19, 2025, as disclosed in the company’s prospectus.
Olema Oncology insider plans additional stock sale under Rule 144. A holder has filed to sell 10,000 shares of Olema common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $238,498.19, targeting an approximate sale date of 02/12/2026.
The 10,000 shares were acquired on 06/15/2020 via restricted stock vesting from the issuer as compensation. In the past three months, the same seller disposed of 3,822 common shares for gross proceeds of $107,069.20 and 100,000 common shares for gross proceeds of $2,873,214.99.
FMR LLC, a Delaware entity, has filed a Schedule 13G reporting beneficial ownership of 5,023,092.35 shares of Olema Pharmaceuticals, Inc. common stock, representing 6.3% of the class as of 12/31/2025. These shares give FMR LLC sole voting power over 5,015,265 shares and sole dispositive power over 5,023,092.35 shares.
Abigail P. Johnson, a U.S. citizen, is also reported as a beneficial owner with sole dispositive power over the same 5,023,092.35 shares and a 6.3% stake, but no sole or shared voting power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Olema Pharmaceuticals.
Olema Pharmaceuticals, Inc. reported that Chief Medical Officer Naseem Zojwalla received two stock option awards on February 2, 2026. She was granted stock options for 250,000 shares of common stock at an exercise price of $25.65 per share, vesting 25% on February 2, 2027 and then in equal monthly installments over the following 36 months, contingent on continued service.
She also received performance stock options covering 106,250 shares at the same exercise price. These are eligible to vest in two performance periods running from February 2, 2026 through December 31, 2029 and December 31, 2030, based on the company’s stock trading above specified price thresholds over a 30‑day average, and subject to her continued service when the Compensation Committee certifies achievement.
Olema Pharmaceuticals granted new equity awards to a senior executive. Chief Discovery & Non-Clinical Development Officer Myles David C. received stock options for 250,000 shares at an exercise price of $25.65 per share, expiring on February 1, 2036.
For this time-based option, 25% of the shares vest on February 2, 2027, with the remainder vesting in equal monthly installments over the following three years, contingent on continued service. He also received 106,250 performance-based stock options at the same exercise price, eligible to vest in two performance periods running from February 2, 2026 through December 31, 2029 and December 31, 2030, based on the company’s stock trading above specified price thresholds and continued service at the certification dates.
Olema Pharmaceuticals’ chief legal officer, Shawnte Mitchell, received new stock-based awards. On February 2, 2026, Mitchell was granted stock options to buy 220,000 shares of common stock at an exercise price of $25.65 per share, expiring February 1, 2036.
These time-based options vest 25% on February 2, 2027, with the remaining shares vesting in equal monthly installments over the following three years, contingent on continued service. Mitchell was also granted 56,250 performance-based stock options at the same $25.65 exercise price, also expiring February 1, 2036.
The performance options may vest in two performance periods beginning February 2, 2026 and ending December 31, 2029 and December 31, 2030, if Olema’s stock achieves specified average price thresholds over a 30-day trading period and the compensation committee certifies achievement, subject to Mitchell’s continued service.
Olema Pharmaceuticals reported new equity awards to President and CEO Sean Bohen. On February 2, 2026, he received a stock option to buy 850,000 shares at an exercise price of $25.65. These options vest 25% on February 2, 2027, with the remainder vesting monthly over the following three years, subject to continued service.
On the same date, Bohen also received 275,000 performance-based stock options at an exercise price of $25.65. These can vest in two performance periods running from February 2, 2026 through December 31, 2029 and December 31, 2030, if Olema’s share price meets specified thresholds over a 30-day trading average and the compensation committee certifies achievement. If his service is terminated without cause, these performance options remain eligible to vest for 12 months.